Eyegate Pharmaceuticals (NASDAQ:EYEG) Given a $5.00 Price Target by HC Wainwright Analysts

Eyegate Pharmaceuticals (NASDAQ:EYEG) received a $5.00 price target from investment analysts at HC Wainwright in a note issued to investors on Tuesday, December 19th. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 284.62% from the stock’s current price.

Eyegate Pharmaceuticals (NASDAQ EYEG) traded up $0.06 during trading hours on Tuesday, hitting $1.30. 723,074 shares of the stock traded hands, compared to its average volume of 389,101. Eyegate Pharmaceuticals has a one year low of $0.90 and a one year high of $3.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market cap of $22.37 and a price-to-earnings ratio of -1.11.

An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC purchased a new position in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 345,524 shares of the specialty pharmaceutical company’s stock, valued at approximately $473,000. Sabby Management LLC owned approximately 2.01% of Eyegate Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 11.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/01/11/eyegate-pharmaceuticals-eyeg-given-a-5-00-price-target-by-hc-wainwright-analysts.html.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply